Skip to main content
Premium Trial:

Request an Annual Quote

Oxford and Qualyst Pen Metabolism Assay Deal

NEW YORK, March 14 (GenomeWeb News) - Oxford Biomedical Research and Qualyst have inked a deal to create a product line of cytochrome P450-inhibition assays to be sold as Accuratet, the companies said today.

 

Under the deal, Qualyst is granting Oxford an exclusive license to manufacture and distribute its CYP activity analysis technology.

 

The first assay to be developed will detect the inhibition of CYP3A4, according to a statement.

 

Financial details were not revealed.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.